Analyst Michael Matson of Needham reiterated a Buy rating on LivaNova, retaining the price target of $64.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors that highlight LivaNova’s strong financial performance and growth potential. The company exceeded expectations in both revenue and earnings per share (EPS) for the third quarter of 2025, prompting an upward revision of its organic revenue and EPS guidance for the year. This improvement is evident in the company’s organic revenue growth, which increased to 12.5% in the third quarter compared to 10.3% in the previous quarter.
Both the Cardiopulmonary and Neuromodulation segments of LivaNova outperformed market expectations, showing stronger growth than in the second quarter. Additionally, while the gross margin saw a slight year-over-year decline, the operating margin improved significantly by 250 basis points. The anticipation of FDA approval for the aura6000 device, designed to treat obstructive sleep apnea, further supports the positive outlook for LivaNova, reinforcing the Buy rating.
In another report released on October 30, Piper Sandler also maintained a Buy rating on the stock with a $80.00 price target.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LIVN in relation to earlier this year.